Fairvalue-Calculator Fairvalue-Calculator
EN DE

AbClon Inc (174900) Fair Value & Analysis

Healthcare · KR · Market cap 565B KRW

Price29,000 KRW
Fair Value5,698 KRW
Upside-80.4%
Quality95/100
Evidence: Low Range 4,273 KRW – 7,122 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AbClon Inc (174900) currently trades at 29,000 KRW, while our model-based Fair Value estimate is 5,698 KRW — implying the stock looks roughly 80.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is AbClon Inc (174900) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5,698 KRW versus a price of 29,000 KRW — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 174900?
Our 21-model fair value for AbClon Inc is 5,698 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 29,000 KRW.
What is the quality score of 174900?
AbClon Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.